Designing Methotrexate Analogs to Improve Efficacy in Rheumatoid Arthritis
Advisor(s)
Dr. John Thurmond; Illinois Mathematics and Science Academy
Discipline
Medical and Health Sciences
Start Date
21-4-2021 10:05 AM
End Date
21-4-2021 10:20 AM
Abstract
The most commonly prescribed disease-modifying antirheumatic drug (DMARD) is methotrexate (MTX) because it is one of the most effective treatments for inflammation and it is relatively safe. Because it is taken at a low dose, it must be taken with other DMARDs to control the disease progression. To improve the efficacy of MTX in rheumatoid arthritis, its structure was modified in SeeSAR and analyzed on Swiss ADME. Six modified MTX analogs were selected from SeeSAR to be analyzed on SwissADME, and three of those compounds have the potential to be more effective than the current DMARD.
Designing Methotrexate Analogs to Improve Efficacy in Rheumatoid Arthritis
The most commonly prescribed disease-modifying antirheumatic drug (DMARD) is methotrexate (MTX) because it is one of the most effective treatments for inflammation and it is relatively safe. Because it is taken at a low dose, it must be taken with other DMARDs to control the disease progression. To improve the efficacy of MTX in rheumatoid arthritis, its structure was modified in SeeSAR and analyzed on Swiss ADME. Six modified MTX analogs were selected from SeeSAR to be analyzed on SwissADME, and three of those compounds have the potential to be more effective than the current DMARD.